Treatment of Lipoxin A(4) and its analogue on low-dose endotoxin induced preeclampsia in rat and possible mechanisms

• Published in: Reproductive toxicology (Elmsford, N.Y.) Vol. 34; no. 4; pp. 677 - 685
• Main Authors: Lin, Feng, Zeng, Pan, Xu, Zhangye, Ye, Duyun, Yu, Xiaofang, Wang, Ni, Tang, Jie, Zhou, Ye, Huang, Yinping
• Format: Journal Article
• Language: English
• Published: United States 01.12.2012
• Subjects: Albuminuria - chemically induced; Albuminuria - drug therapy; Albuminuria - physiopathology; Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Apoptosis - drug effects; Blood Pressure - drug effects; Cell Line; Cell Proliferation - drug effects; Cytokines - genetics; Female; Heptanoic Acids - pharmacology; Heptanoic Acids - therapeutic use; Humans; Lipopolysaccharides; Lipoxins - pharmacology; Lipoxins - therapeutic use; Pre-Eclampsia - chemically induced; Pre-Eclampsia - drug therapy; Pre-Eclampsia - physiopathology; Pregnancy; Rats; Rats, Sprague-Dawley; RNA, Messenger - metabolism

Preeclampsia (PE) is known to represent an exaggerated maternal inflammatory response to pregnancy. Lipoxin A(4) (LXA(4)), considered as an endogenous stop signal in inflammation, has been extensively studied pre clinically for its inflammatory pro-resolving effects. Thus, in the current study, we t...